Increased Transforming Growth Factor-β Levels Associated with Cardiac Adverse Events in Hypertrophic Cardiomyopathy

Clinical Cardiology

Volumn 38, Issue 6, 2015, Pages 371-377

  Ayça, Burak ^a   Sahin, Irfan ^a   Kucuk, Suat Hayri ^a   Akin, Fatih ^b   Kafadar, Didem ^a   Avşar, Murat ^a   Avci, Ilker Ilhan ^a   Gungor, B D L D A L ^c   Okuyan, Ertugrul ^a   Dinckal, Mustafa Hakan ^a  

^a Ba cilar Education and Research Hospital   (Turkey)

^b MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^c Siyami Ersek Cardiovascular Training and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; UREA; WARFARIN; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE HEART FAILURE; ADULT; ANALYSIS OF COVARIANCE; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE SEPTUM; HOSPITALIZATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEUKOCYTE COUNT; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; BLOOD; ECHOGRAPHY; MIDDLE AGED; MORTALITY; PROGNOSIS; YOUNG ADULT;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84931955109     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22404     Document Type: Article

References (40)

1. Maskatia SA,. Hypertrophic cardiomyopathy: infants, children, and adolescents. Congenit Heart Dis. 2012; 7: 84-92.
2. Amano Y, Takeda M, Tachi M, et al., Myocardial fibrosis evaluated by Look-Locker and late gadolinium enhancement magnetic resonance imaging in apical hypertrophic cardiomyopathy: association with ventricular tachyarrhythmia and risk factors. J Magn Reson Imaging. 2014; 40: 407-412.
3. Subasic K., Living with hypertrophic cardiomyopathy. J Nurs Scholarsh. 2013; 45: 371-379.
4. Hernández-Romero D, Orenes-Piñero E, García-Honrubia A, et al., Involvement of the -420C > G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Intern Med. 2014. doi: 10.1111/joim.12334.
5. Brouwer WP, van Dijk SJ, Stienen GJ, et al., The development of familial hypertrophic cardiomyopathy: from mutation to bedside. Eur J Clin Invest. 2011; 41: 568-578.
6. Song BG, Yang HS, Hwang HK, et al., Correlation of electrocardiographic changes and myocardial fibrosis in patients with hypertrophic cardiomyopathy detected by cardiac magnetic resonance imaging [retraction appears in Clin Cardiol. 2013]. Clin Cardiol. 2013; 36: 31-35.
7. Zeisberg EM, Tarnavski O, Zeisberg M, et al., Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007; 13: 952-961.
8. Hina K, Iwasaki K, Nogami K, et al., Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value. Clin Cardiol. 1993; 16: 403-407.
9. Teekakirikul P, Eminaga S, Toka O, et al., Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-β. J Clin Invest. 2010; 120: 3520-3529.
10. Medina C, Santos-Martinez MJ, Santana A, et al., Transforming growth factor-β type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol. 2011; 224: 461-472.
11. Porte J, Jenkins G,. Assessment of the effect of potential antifibrotic compounds on total and αVβ6 integrin-mediated TGF-β activation. Pharmacol Res Perspect. 2014. doi: 10.1002/prp2.30.
12. Cai Y, Zhou CH, Fu D, et al., Overexpression of Smad ubiquitin regulatory factor 2 suppresses transforming growth factor-β-mediated liver fibrosis. J Dig Dis. 2012; 13: 327-334.
13. Rosenkranz S, Flesch M, Amann K, et al., Alterations of β adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β(1). Am J Physiol Heart Circ Physiol. 2002; 283: 1253-1262.
14. Meyer A, Wang W, Qu J, et al., Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood. 2012; 119: 1064-1074.
15. Li RK, Li G, Mickle DA, et al., Overexpression of transforming growth factor-β1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation. 1997; 96: 874-881.
16. Li G, Li RK, Mickle DA, et al., Elevated insulin-like growth factor-I and transforming growth factor-β1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy: a possible mechanism. Circulation. 1998;II: 144-149.
17. Dobaczewski M, Chen W, Frangogiannis NG,. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011; 51: 600-606.
18. Bujak M, Frangogiannis NG,. The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007; 74: 184-195.
19. Cuspidi C, Negri F, Muiesan ML, et al., Prevalence and severity of echocardiographic left ventricular hypertrophy in hypertensive patients in clinical practice. Blood Press. 2011; 20: 3-9.
20. Elliott PM, Anastasakis A, Borger MA, et al., 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35: 2733-2779.
21. Li G, Borger MA, Williams WG, et al., Regional overexpression of insulin-like growth factor-I and transforming growth factor-β1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2002; 123: 89-95.
22. Almendral JL, Shick V, Rosendorff C, et al., Association between transforming growth factor-β(1) and left ventricular mass and diameter in hypertensive patients. J Am Soc Hypertens. 2010; 4: 135-141.
23. Villar AV, Cobo M, Llano M, et al., Plasma levels of transforming growth factor-β1 reflect left ventricular remodeling in aortic stenosis. PLoS One. 2009; 4: e8476.
24. Timmer SA, Germans T, Brouwer WP, et al., Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011; 13: 1283-1289.
25. Fatkin D, McConnell BK, Mudd JO, et al., An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest. 2000; 106: 1351-1359.
26. Ahn HS, Kim HK, Park EA, et al., Coronary flow reserve impairment in apical vs asymmetrical septal hypertrophic cardiomyopathy. Clin Cardiol. 2013; 36: 207-216.
27. Gavallér H, Sepp R, Csanády M, et al., Hypertrophic cardiomyopathy is associated with abnormal echocardiographic aortic elastic properties and arteriograph-derived pulse-wave velocity. Echocardiography. 2011; 28: 848-852.
28. O'Hanlon R, Pennell DJ,. Cardiovascular magnetic resonance in the evaluation of hypertrophic and infiltrative cardiomyopathies. Heart Fail Clin. 2009; 5: 369-387.
29. Menon SC, Eidem BW, Dearani JA, et al., Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents [published correction appears in J Am Soc Echocardiogr. 2010;23:222]. J Am Soc Echocardiogr. 2009; 22: 1327-1334.
30. Moreo A, Ambrosio G, De Chiara B, et al., Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging. 2009; 2: 437-443.
31. Rubinshtein R, Glockner JF, Ommen SR, et al., Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010; 3: 51-58.
32. Inada K, Seiler J, Roberts-Thomson KC, et al., Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011; 22: 41-48.
33. Abe M, Okada K, Matsumoto K,. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide. Expert Opin Drug Metab Toxicol. 2009; 5: 1285-1303.
34. Matt P, Schoenhoff F, Habashi J, et al,; GenTAC Consortium. Circulating transforming growth factor-β in Marfan syndrome. Circulation. 2009; 120: 526-532.
35. Xiao H, Lei H, Qin S, et al., TGF-β1 expression and atrial myocardium fibrosis increase in atrial fibrillation secondary to rheumatic heart disease. Clin Cardiol. 2010; 33: 149-156.
36. Felkin LE, Lara-Pezzi E, George R, et al., Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transplant. 2009; 28: 117-122.
37. Frantz S, Hu K, Adamek A, et al., Transforming growth factor-β inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008; 103: 485-492.
38. Hillebrand M, Millot N, Sheikhzadeh S, et al., Total serum transforming growth factor-β1 is elevated in the entire spectrum of genetic aortic syndromes. Clin Cardiol. 2014; 37: 672-679.
39. Edgley AJ, Krum H, Kelly DJ,. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. Cardiovasc Ther. 2012; 30: e30-e40.
40. Geske JB, McKie PM, Ommen SR, et al., B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013; 61: 2456-2460.